Interstitial Lung Disease News and Research

RSS

Interstitial lung disease (ILD) is a broad group of lung diseases comprising of more than a hundred distinct disorders. All of these involve scarring or inflammation of the interstitial lung tissue and affect the volume of oxygen that can reach the bloodstream via the respiratory system.

Researchers identify genetic basis for anti-neutrophil cytoplasmic antibody-associated vasculitis

Autoimmune disease is fundamentally a mystery: whyever should an organism systematically set out to harm itself?

4 Nov 2020

Researchers assess molecular basis of SARS-CoV-2 severity and poor outcomes in lung disease

A recent study published on the preprint server bioRxiv in October 2020 shows that in patients with chronic lung disease, the pattern of gene expression in the different types of cell changes such that the lung epithelium is prepared to tackle SARS-CoV-2 infection. Also, the altered gene programs have an impact on the immune response.

22 Oct 2020

Genetic variant in Japanese population increases risk of interstitial lung disease among RA patients

In many cases, a complex interplay between our genes and the environment governs whether or not we will develop a certain disease. Interestingly though, researchers are discovering that the genetic component of disease predisposition may depend on our ethnic background.

10 Aug 2020

Reducing the incidence of drug-induced interstitial lung disease in breast cancer patients

Announcing a new article publication for BIO Integration journal. In this case report the authors Zijun Zhao, Zhanghai He, Hongyan Huang, Jiewen Chen, Shishi He, Ailifeire Yilihamu and Yan Nie from Sun Yat-sen University, Guangzhou, China consider drug-induced interstitial lung disease in breast cancer patients.

27 Jul 2020

Methotrexate is not an additional risk factor for interstitial lung disease in RA patients

Patients with rheumatoid arthritis (RA) often suffer from what is referred to as interstitial lung disease (ILD).

7 Jul 2020

Air pollution may lead to interstitial lung diseases

More research must be done to investigate the role of air pollution on the epigenome in patients with interstitial lung diseases (ILDs), in order to develop strategies that minimize the effects of these pollutants, according to a new article published online in the American Thoracic Society's American Journal of Respiratory and Critical Care Medicine.

1 Jul 2020

Researchers use new technique to improve the ability to model lung diseases

Using a combination of pluripotent stem cells (cells that can potentially produce any cell or tissue type) and machine learning (artificial intelligence that allows computers to learn automatically), researchers have improved how they generate lung cells.

30 Jan 2020

UAB study suggests potential treatment target for IPF

Long-held dogma says lung fibrosis in diseases like idiopathic pulmonary fibrosis, or IPF, results from recurrent injury to alveolar epithelium that is followed by dysregulated repair.

12 Nov 2019

Nintedanib drug can benefit patients with broad range of scarring lung diseases

Nintedanib, a medication approved for the treatment of idiopathic pulmonary fibrosis, slows the decline in lung function among patients with a broad range of scarring lung diseases.

30 Sep 2019

FDA approves first drug to treat patients with rare lung condition

The U.S. Food and Drug Administration today approved Ofev (nintedanib) capsules to slow the rate of decline in pulmonary function in adults with interstitial lung disease associated with systemic sclerosis or scleroderma, called SSc-ILD. It is the first FDA-approved treatment for this rare lung condition.

7 Sep 2019

Association found between gene variant and lung disease in the form of systemic vasculitis

University of Tsukuba-led team reveals the association between a gene variant and a lung disease in the form of systemic vasculitis particularly prevalent in the Japanese, potentially providing a target for future therapies.

13 Mar 2019

Researchers find cause, treatment for CVID lung disease using precision medicine

Researchers have identified that dysfunction of a specific immune cell, called B cells, underlies lung disease that affects patients with the rare immunological disorder known as common variable immunodeficiency.

8 Mar 2019

A holistic approach key to minimize treatment complexity in patients with interstitial lung disease

Patients with interstitial lung disease—a group of disorders causing progressive scarring of lung tissue—are often prescribed various medications that specifically target their disease and others that treat their symptoms.

21 Feb 2019

New clinical practice guideline on home oxygen therapy for children

The American Thoracic Society has developed a new clinical practice guideline for home oxygen therapy for children. The guideline appears in the Feb. 1 edition of the Society's American Journal of Respiratory and Critical Care Medicine.

4 Feb 2019

Researchers identify link between mucus in the small airways and pulmonary fibrosis

A team of investigators led by members of the University of Colorado School of Medicine faculty at CU Anschutz Medical Campus has identified a connection between mucus in the small airways and pulmonary fibrosis.

18 Dec 2018

FDA approves LORBRENA for treatment of patients with ALK-positive metastatic NSCLC

Pfizer Inc. today announced that the U.S. Food and Drug Administration has approved LORBRENA, a third-generation anaplastic lymphoma kinase tyrosine kinase inhibitor for patients with ALK-positive metastatic non-small cell lung cancer whose disease has progressed on crizotinib and at least one other ALK inhibitor for metastatic disease; or whose disease has progressed on alectinib or ceritinib as the first ALK inhibitor therapy for metastatic disease.

5 Nov 2018

Toxic effects of drugs in the lungs 'more widespread than thought'

A systematic review of research has revealed that the toxic effects on the lung of drugs commonly taken to treat a range of common conditions is much more widespread than thought.

29 Oct 2018

Researchers identify common genetic connection in lung conditions

An international research team led by members of the University of Colorado School of Medicine faculty has identified a genetic connection between rheumatoid arthritis-associated interstitial lung disease and idiopathic pulmonary fibrosis.

22 Oct 2018

Takeda announces positive Phase 3 ALTA-1L data in first-line therapy for advanced ALK+ NSCLC

Takeda Pharmaceutical Company Limited today announced that intracranial efficacy data from the Phase 3 ALTA-1L (ALK in Lung Cancer Trial of BrigAtinib in 1st Line) trial showed improved intracranial progression-free survival (PFS) and intracranial objective response rate (ORR) with ALUNBRIG (brigatinib) compared to crizotinib among anaplastic lymphoma kinase-positive (ALK+) non-small cell lung cancer (NSCLC) patients.